Register Login

INTELLIA THERAPEUTICS, INC. (NTLA)

(10% Negative) INTELLIA THERAPEUTICS, INC. (NTLA) Announces Delay in attacks Trials for six-month efficacy evaluation period Due to Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot April 27, 2026, 1:14 p.m.

    📋 INTELLIA THERAPEUTICS, INC. (NTLA) - Clinical Trial Update

    Filing Date: 2026-04-27

    Accepted: 2026-04-27 09:13:36

    Event Type: Clinical Trial Update

    Event Details:

    INTELLIA THERAPEUTICS, INC. (NTLA) Announces Clinical Trial Update INTELLIA THERAPEUTICS, INC. (NTLA) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: attacks, Results
    • Diseases/Conditions: six-month efficacy evaluation period, Hereditary Angioedema
    • Clinical Stage: clinical trial, Phase 3
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Regulatory Process
    • Collaboration: the U.S. Food and Drug Administration

    🔬 Clinical Development Pipeline (INTELLIA THERAPEUTICS, INC.):

    Product Type Development Stage Therapeutic Area Source
    Normal Saline as Placebo DRUG Phase PHASE3 Neuromuscular Disease ClinicalTrials.gov
    NTLA-2002 BIOLOGICAL Phase PHASE3 Hereditary Angioedema ClinicalTrials.gov
    LNP1265 DRUG Phase PHASE1 Hemophilia B ClinicalTrials.gov
    REGV131 DRUG Phase PHASE1 Hemophilia B ClinicalTrials.gov
    nexiguran ziclumeran BIOLOGICAL Phase PHASE3 Neuromuscular Disease ClinicalTrials.gov
    Biological NTLA-3001 BIOLOGICAL Phase PHASE1 Lung Disease ClinicalTrials.gov
    Placebo DRUG Phase PHASE3 Transthyretin Amyloidosis (ATTR) With Cardiomyopathy ClinicalTrials.gov
    Normal Saline IV Administration OTHER Phase PHASE1 Hereditary Angioedema ClinicalTrials.gov
    Biological NTLA-2002 BIOLOGICAL Phase PHASE1 Hereditary Angioedema ClinicalTrials.gov
    Arm 2: NTLA-5001 GENETIC Phase PHASE1 Acute Myeloid Leukemia ClinicalTrials.gov
    Arm 1: NTLA-5001 GENETIC Phase PHASE1 Acute Myeloid Leukemia ClinicalTrials.gov
    NTLA-2001 BIOLOGICAL Phase PHASE1 Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: INTELLIA THERAPEUTICS, INC.
    • Ticker Symbol: NTLA

Search

News categories